[1] 杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查. 实用肝脏病杂志, 2022, 25(2): 153-156.
[2] Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol,2022,76(2):446-457.
[3] Michelotti A, de Scordilli M, Palmero L, et al. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells,2021,10(8):2034.
[4] Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol,2018,68(2):280-295.
[5] Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology,2007,45(6):1366-1374.
[6] Pfister D, Nú?ez NG, Pinyol R, et al.?NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature,2021,592(7854):450-456.
[7] Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep,2021,3(2):100231.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018, 69(1):182-236.
[9] Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol,2017,8(6):429-436.
[10] Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease-changing trends and specific challenges. Curr Med Res Opin,2020, 36(2):235-243.
[11] Yip TC, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC. J Hepatol,2022,76(3):726-734.
[12] Albano E, Sutti S. The paradox role of cytotoxic T-lymphocytes in NAFLD-associated hepatocellular carcinoma. Hepatobiliary Surg Nutr,2021, 10(5):705-707.
[13] Pfister D, Nú?ez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature,2021,592(7854):450-456.
[14] Koh YX, Tan HJ, Liew YX, et al. Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J?Am Coll Surgeons,2019,229: 467-478.e1.
[15] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018, 69(1):182-236.
[16] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2018,68(2):723-750.
[17] Koh YX, Tan HJ, Liew YX, et al. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. J Am Coll Surg,2019, 229(5):467-478.e1.
[18] Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med,1996,334(11):693-699.
[19] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers,2021,7(1):6.
[20] 周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展. 实用肝脏病杂志, 2022, 25(2): 157-160. |
